Dsh homolog DVL3 mediates resistance to IGF-1R inhibition by regulating IGF-RAS signalling
The informal name for combining BPC-157 and TB-500, two peptides studied for tissue repair
In preclinical studies, ALCAR reduced oxidative damage markers (lipid peroxidation, oxidized nucleotides, nitrotyrosine) in aged rat brains, while LCAR did not, despite both compounds similarly increasing ambulatory activity and tissue carnitine levels.[5] ALCAR also decreased infarction size in stroke models, whereas LCAR showed no protective effect in vivo, though both were neuroprotective in vitro.[6] These differences likely reflect ALCARs ability to donate acetyl groups for acetylcholine synthesis, energy production, and neurotransmitter metabolism.[2][7] For cardiovascular and metabolic applications, the compounds appear more comparable
This degree of glucose lowering often enables patients to achieve their individualised HbA1c targets as recommended by NICE (typically 48 mmol/mol for most adults with type 2 diabetes, or 53 mmol/mol for those at risk of hypoglycaemia)
& Zopf, Y
The BPC-157 Question A fifteen-amino-acid peptide named BPC-157 has spent fifty years on the margins of medicine and is now headed for an FDA advisory review
